Last updated: June 21, 2022. Click here to view log of changes to our data and website.

COVID-19 living
network meta-analysis

Drugs, antibodies, and cellular therapies for
treatment and prophylaxis against COVID-19

Drug
Treatments

Corticosteroids, interleukin-6 inhibitors receptor antagonists, and janus kinase inhibitors probably reduce mortality and confer other important benefits in patients with severe covid-19. Molnupiravir probably reduces admission to hospital in patients with non-severe covid-19.

image__patients

163k

Patients

image__patients

463

studies

image__patients

180

Interventions

image__patients

19

outcomes

Select an intervention or specify a treatment comparison to view the summary of findings table

View efficacy and safety of all drug treatments compared to standard care

Prophylaxis

Hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Because of serious risk of bias and very serious imprecision, it is highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduce the risk of SARS-CoV-2 infection.

image__patients

14k

Patients

image__patients

32

studies

image__patients

17

Interventions

image__patients

6

outcomes

Select an intervention or specify a treatment comparison to view the summary of findings table

View efficacy and safety of all prophylactic interventions compared to standard care

Antibodies &
Cellular Therapies

There is no clear effect of bamlanivimab, convalescent plasma, or IVIG on patient- important outcomes. Properly evaluating the safety and efficacy of humoral and cellular therapies for the treatment of covid-19 will requires data from additional large randomised trials.

image__patients

16k

Patients

image__patients

46

studies

image__patients

14

Interventions

image__patients

16

outcomes

Select an intervention or specify a treatment comparison to view the summary of findings table

View efficacy and safety of all antibodies and cellular therapies compared to standard care

This website provides up-to-date information about the use of pharmaceuticals, antiviral antibodies, and blood products in treatment and prevention of COVID-19. The evidence presented is the joint effort of an international group of researchers. The core group is based at McMaster University, and collaborates closely with the Magic Evidence Ecosystem Foundation and The BMJ. We also work independently of, but in collaboration with, The World Health Organization. This work is partially funded by the Canadian Institutes of Health Research operating grants VR4-172738 and MM1-174897.

©2021 by COVID-19 Living Network Meta-Analysis Terms of Service